What is Important in Patients with COVID-19 Associated with Myocardial Infarction?
In this letter we have focused on two important issues, possible risk of MI in patients who are infected with SARS- Cov-2 and different therapeutic protocols that are currently applying for management of them which may be harmful in this group of patients with heart disorders who are infected with SARS- Cov-2 patients and must be replaced with safer ones. So, Calcineurin inhibitor and cyclosporine are more likely to have less cardiac side effects in these patients. Finally, it should be considered that Calcineurin inhibitor and cyclosporine require extensive clinical trial for evaluation of their effects in patients with heart disorders who are infected with SARS- Cov-2 patients.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.